Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, covering common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR. Alaunos is developing non-viral gene transfer-based cell therapies to effectively access and treat the millions of people diagnosed globally each year with solid tumors by weaponizing the body’s immune system.